BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ImmunoVaccine Technologies Inc. (IVT) to Acquire Immunotope, Inc.


12/10/2007 7:22:07 AM

HALIFAX, Dec. 10 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.

The acquisition will bring together IVT's signature VacciMax(R) platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. The combined clinical-stage company will continue to support Immunotope's ongoing Phase 1 immunotherapeutic vaccine clinical trial in ovarian and breast cancer patients at Duke University Comprehensive Cancer Center.

"IVT is continuously evaluating partnership opportunities," remarked Dr. Randal Chase, president and CEO of IVT. "With this acquisition, we enhance our research capabilities, expand our operations into the U.S., and gain a distinct competitive advantage for our immunotherapy products."

Dr. Ramila Philip, President and CSO of Immunotope commented, "The complementary scientific and management skills of IVT and Immunotope will enable us to leverage our respective strengths and increase our capability to develop therapeutic and prophylactic vaccines. Therapeutic cancer vaccines that combine the right antigens with a powerful delivery system have the potential to treat cancer early and prevent recurrence."

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, with potential applications in cervical, melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases.

www.immunovaccine.com

Immunotope is a clinical stage biotechnology company developing immunotherapy products for the treatment of cancer and chronic viral infections. Immunotope focuses on the critical, unmet need to diagnose cancer at its earliest stages and to provide effective treatments that destroy tumors and prevent recurrence and metastasis. The company's lead product, the IMT-1012 multivalent therapeutic vaccine, is now being evaluated in a Phase I clinical trial at the Duke University Comprehensive Cancer Center in advanced-stage ovarian and breast cancer patients.

www.immunotope.com

CONTACT: Contact: ImmunoVaccine Technologies Inc.: Brian Lowe, Vice
President, (902) 492-1819, bl.ivt@immunovaccine.com; Media Contact: Impact
Communications Group: Jennifer Ayotte, (902) 209-4704,
jayotte@impactcommunications.ca; Immunotope, Inc.: Lorraine Keller, Ph.D.,
Executive Vice President, (215) 589-6352, lkeller@immunotope.com; Media
Contact: Richard Lewis Communications, Inc.: Gregory Tiberend, (212)
827-0020, gtiberend@rlcinc.com or Meghan Feeks, mfeeks@rlcinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES